智通财经网·2025-10-28 10:03Core Viewpoint - Fosun Pharma (02196) announced the board's decision to propose a spin-off listing of its subsidiary, Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd., on the Hong Kong Stock Exchange by October 28, 2025 [1] Company Overview - Fosun Antigen was established in July 2012 and is primarily focused on the research, development, production, and sales of human vaccines [1] - As of the announcement date, Shanghai Fosun Pharma Industrial Development Co., Ltd. holds a 70.08% stake in Fosun Antigen, while 17 other shareholders own the remaining 29.92% [1] Product Development - Fosun Antigen has developed a technical platform for both bacterial and viral vaccines [1] - The company has received approval for several self-developed human vaccines in mainland China, including: - Rabies vaccine (Vero cells) - Freeze-dried rabies vaccine (Vero cells) - Trivalent influenza virus split vaccine - Quadrivalent influenza virus split vaccine [1] - The 13-valent pneumococcal conjugate vaccine is currently in Phase III clinical trials [1] - The freeze-dried human rabies vaccine (human diploid cells) and 24-valent pneumococcal polysaccharide vaccine are in Phase I clinical trials [1] - The 23-valent pneumococcal polysaccharide vaccine has received clinical trial approval [1]